
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries is positioned for substantial growth, with projected sales for Ajovy and Uzedy expected to increase significantly, by 17% and 45% year-over-year, respectively, contributing to a diversified revenue stream. The company is anticipated to achieve an uplift in EBITDA margins through a strategic shift to a higher-value product base, along with ongoing growth in cash flows anticipated beyond 2027. Additionally, the strong performance of Austedo with US sales reaching $725 million in 4Q25 showcases the potential for further market share gains and pricing improvements, indicating a positive trajectory for the company's financial health.
Bears say
Teva Pharmaceutical Industries is facing a challenging outlook primarily due to expected revenue declines in 1Q26 and 4Q26, attributed to inventory patterns and pricing pressures related to the implementation of the Inflation Reduction Act (IRA). The company’s generics revenues missed estimates by 3% in 4Q25, reflecting an 11% year-over-year decline in US total prescriptions, which signals ongoing demand weakness in this segment. Additionally, ongoing risks include regulatory uncertainties, litigation, and concerns regarding the successful execution of their pharmaceutical pipeline, all of which threaten to undermine Teva's financial stability and growth trajectory.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares